FDA Class I Recall: Boulla LLC's VitalityXtra Capsules Contain Undeclared Sildenafil and Diclofenac, Lacking NDA/ANDA Approval
Boulla LLC faces a Class I FDA recall (D-0083-2025) for its VitalityXtra Capsules, 500 mg, distributed by VitalityXtra. The product, marketed without an approved NDA/ANDA, contains undeclared sildenafil and diclofenac. This presents significant regulatory and safety risks, demanding immediate action from procurement and regulatory affairs teams to assess supply chain exposure and ensure product integrity.
FDA Class I Recall: Unapproved Drug Status and Undeclared Active Ingredients in VitalityXtra
The U.S. Food and Drug Administration (FDA) has classified the recall of Boulla LLC's VitalityXtra Capsules, 500 mg, as Class I, indicating a high probability of serious adverse health consequences or death. Initiated by Boulla LLC on November 4, 2024, under recall number D-0083-2025, this action stems from two critical violations. Firstly, the product was marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), a fundamental regulatory requirement for pharmaceutical products in the United States. This means the product has not undergone the rigorous FDA review process to ensure its safety, efficacy, and quality. Secondly, laboratory analysis revealed the presence of undeclared active pharmaceutical ingredients (APIs): sildenafil and diclofenac. Sildenafil, a phosphodiesterase-5 (PDE5) inhibitor, is the active ingredient in prescription medications for erectile dysfunction, and its undeclared presence poses significant risks, particularly for individuals with cardiovascular conditions, who may experience dangerous drops in blood pressure when combined with nitrates. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), carries risks of gastrointestinal bleeding, cardiovascular events, and kidney damage, especially with prolonged use or in susceptible populations. For procurement directors and regulatory affairs heads, this event underscores the severe risks associated with products bypassing established regulatory pathways. Sourcing or distributing such products exposes businesses to substantial legal liabilities, reputational damage, and potential enforcement actions from the FDA, necessitating immediate review of all 'supplement' product lines for similar compliance gaps.
Boulla LLC's Operational Footprint and Product Distribution
Boulla LLC, identified as the recalling firm based in Sacramento, CA, at 2108 N ST #7929, 95816, is responsible for the manufacturing or initial distribution of the implicated VitalityXtra Capsules. The product, packaged in 10-count blisters within cartons, was distributed by VitalityXtra, located in San Francisco, CA. The affected lot is 230811, with an expiration date of August 11, 2025. This recall has a nationwide distribution pattern within the United States, indicating a broad market presence for the non-compliant product. While specific facility details such as an FEI number or production capacity are not publicly available in the immediate recall notice, the firm's role as the primary entity initiating this voluntary recall highlights its direct responsibility for product quality and regulatory adherence. For supply chain VPs and business development executives, this situation emphasizes the critical need for comprehensive due diligence on all upstream suppliers, even those operating within the United States. The absence of an approved NDA/ANDA and the inclusion of undeclared APIs signal a profound breakdown in quality control and regulatory compliance at the source. Any entity involved in the distribution or sale of VitalityXtra Capsules, regardless of their direct relationship with Boulla LLC, faces immediate operational challenges, including inventory identification, quarantine, and reverse logistics, alongside potential legal and financial repercussions from consumers and regulatory bodies.
Supply Chain Exposure: Mitigating Risks for Downstream Partners
The nationwide distribution of Boulla LLC's VitalityXtra Capsules creates significant supply chain exposure for any entity involved in its downstream movement, including distributors, retailers, and e-commerce platforms. Procurement directors must immediately initiate a comprehensive audit to identify and quarantine all affected product lots (Lot #: 230811) within their inventory and distribution networks. Failure to do so not only prolongs consumer exposure to dangerous undeclared active ingredients like sildenafil and diclofenac but also exacerbates a firm's legal and reputational risks. Regulatory affairs heads must ensure that all communication with the FDA and consumers regarding this recall is accurate, timely, and compliant with federal regulations. This incident serves as a stark reminder that even products marketed as 'supplements' can carry pharmaceutical-grade risks if not properly vetted. Businesses must implement rigorous vendor qualification programs that include regular audits, comprehensive analytical testing of incoming materials and finished products, and verification of regulatory approvals for all ingredients and formulations. The financial implications extend beyond recall costs to potential lawsuits, fines, and the irreparable damage to brand trust, underscoring the commercial imperative of proactive risk management in the supply chain.
Strategic Sourcing for Sildenafil and Diclofenac: Ensuring Regulatory Compliance
This Class I recall of VitalityXtra Capsules, driven by the presence of undeclared sildenafil and diclofenac, highlights a critical vulnerability in the sourcing of active pharmaceutical ingredients (APIs) and finished drug products. For procurement teams, the immediate takeaway is the absolute necessity of sourcing all APIs, especially potent compounds like sildenafil (a PDE5 inhibitor) and diclofenac (an NSAID), exclusively from FDA-approved manufacturers with robust cGMP (current Good Manufacturing Practice) compliance. This incident underscores the perils of relying on unverified or non-transparent supply channels, which can introduce unapproved and potentially harmful substances into the market. Business development executives exploring new product formulations or market entries must prioritize partners who can demonstrate a clear regulatory pathway, including approved NDAs or ANDAs, for their products. The qualification process for API suppliers must be exhaustive, encompassing facility audits, documentation review (e.g., Drug Master Files), and a proven track record of regulatory adherence. While specific alternative suppliers for Boulla LLC are not detailed in our knowledge graph, the broader market for legitimate sildenafil and diclofenac APIs is well-established, provided procurement teams focus on reputable, globally recognized pharmaceutical chemical manufacturers. This event reinforces that the cost of non-compliance, both in terms of financial penalties and brand erosion, far outweighs any perceived savings from circumventing rigorous sourcing protocols.
Boulla LLC's Regulatory Compliance Record and Future Outlook
Our intelligence indicates no prior FDA Warning Letters, 483s, or Import Alerts specifically linked to Boulla LLC within our knowledge graph. This Class I recall, D-0083-2025, therefore represents a significant and severe regulatory event for the company. The classification of 'Class I' by the FDA is reserved for situations where there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. The undeclared presence of sildenafil and diclofenac, combined with the lack of an approved NDA/ANDA for VitalityXtra Capsules, unequivocally justifies this high-severity classification. For regulatory affairs heads, this incident serves as a critical case study: even companies without a documented history of prior violations can face severe enforcement actions for fundamental breaches of drug manufacturing and marketing regulations. The ongoing status of the recall means that the FDA will continue to monitor Boulla LLC's efforts to remove the product from the market and address the root causes of the non-compliance. Future FDA actions could include an official Warning Letter, injunctions, or product seizures if the firm's remediation efforts are deemed inadequate. This situation demands that any company considering Boulla LLC as a future partner, or currently engaged with them, conduct an immediate and thorough re-evaluation of their risk profile, recognizing that a single, severe regulatory lapse can have profound and lasting commercial implications.
Remediation Timeline and What Happens Next for Market Participants
Boulla LLC initiated this voluntary Class I recall on November 4, 2024, with the FDA's Center classification occurring on December 2, 2024, and the report date on December 11, 2024. The recall status is currently 'Ongoing,' indicating that the process of identifying, removing, and accounting for all affected VitalityXtra Capsules from the nationwide distribution chain is still underway. For procurement directors and supply chain VPs, this means the immediate priority remains ensuring that no further units of Lot #: 230811 (Exp: 08/11/2025) are distributed or sold. Establishing clear return pathways and managing reverse logistics efficiently are crucial to minimize financial losses and mitigate public health risks. Regulatory affairs teams should anticipate potential follow-up actions from the FDA, which could include inspections of Boulla LLC's facilities to assess corrective and preventive actions (CAPA). While the specific timeline for FDA enforcement is not fixed, the severity of a Class I recall involving undeclared APIs typically leads to heightened scrutiny. This event underscores the need for continuous vigilance across the chemical and life sciences industry. Companies must implement robust post-market surveillance and rapid response protocols to effectively manage recalls, protecting both consumer safety and corporate integrity in a dynamic regulatory landscape. Proactive engagement with regulatory intelligence is paramount to navigate such high-stakes events successfully.